Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis
Study context
- Population
- Critically ill patients with intra-abdominal candidiasis (IAC)
Methodological detailsAll current pharmacokinetic (PK)/pharmacodynamic (PD) studies relating to IAC reviewed for strengths and limitations
- All current PK/PD studies relating to IAC reviewed for strengths and limitations
Main finding
As reported in the abstract
- IAC presents specific PK alterations and PD challenges that risk suboptimal antifungal exposure at the infection site in critically ill patients
- Individualized approach to antifungal dosing advocated
- No comprehensive guidance currently exists on optimising antifungal dosing in IAC among the critically ill
Original publication
Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis. Crit Care. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →